Josep Maria Piulats Rodriguez, MD, PhD, discusses next steps for validating predictive biomarkers of efficacy to treatment with talazoparib plus enzalutamide in mCRPC.
Josep Maria Piulats Rodriguez, MD, PhD
Advertisement
Articles by Josep Maria Piulats Rodriguez, MD, PhD
Josep Maria Piulats Rodriguez, MD, PhD, discusses the rationale for identifying predictive biomarkers for talazoparib plus enzalutamide in mCRPC.
Josep Maria Piulats Rodriguez, MD, discusses an analysis evaluating predictive biomarkers for treatment with talazoparib plus enzalutamide in mCRPC.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
The OncFive: Top Oncology Articles for the Week of 1/25
3
HPV Vaccination and Evolving Screening Strategies Continue to Shape Cervical Cancer Prevention Efforts
4
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
5